WST Valuation Report 2026-07-25

West Pharmaceutical Services benefits from stable demand in the pharmaceutical supply sector, particularly for injectable drugs and increasingly, self-administered therapies like GLP-1 agonists. Recent Q2 2026 results show 13.8% revenue growth to $872.3 million, with adjusted EPS exceeding expectations at $2.37, driven by a shift towards higher-margin, high-value products now comprising 49% of revenue. Full-year forecasts have been raised to $3.345–$3.380 billion revenue and $8.85–$9.05 EPS, reflecting confidence in continued double-digit organic growth. Strategic divestitures, like the SmartDose sale, are streamlining the portfolio towards differentiated offerings. While GLP-1 demand is a near-term tailwind, concentration risk warrants monitoring. The company focuses on operational efficiency, working capital optimization, and returns capital to shareholders via a $0.22 quarterly dividend. Macroeconomic stability supports this outlook, though inflationary pressures require mitigation through pricing power and cost control. Over the past four quarters, the company has shifted from aggressive growth to a more defensive posture focused on core competencies and operational efficiency, evidenced by restructuring and portfolio optimization. Risks include crude oil price volatility, regulatory scrutiny, supply chain fragility, and competitive pressures. Despite these, WST demonstrates a strengthening economic moat and a strategic focus on high-value products, positioning it for continued revenue and margin expansion.